Mereo reports Phase II data for COPD candidate acumapimod

Mereo BioPharma Group plc (LSE:MPH) reported top-line data from a Phase II trial in 282 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) showing that low- and high-dose acumapimod

Read the full 313 word article

User Sign In